Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Domain Therapeutics announces successful completion of the first milestone in its Research Agreement

Domain Therapeutics announces successful completion of the first milestone in its Research Agreement with Takeda Pharmaceutical

Strasbourg, France, November 4, 2009 - Domain Therapeutics, a drug discovery company focused on G Protein-Coupled Receptors (GPCRs), announces today that it has successfully completed the first milestone in its research agreement with Takeda Pharmaceutical. This research agreement initially concerns the use of Domain's DTect-All(TM) technology for the discovery of novel drug candidates for GPCRs of interest to Takeda.

'Achievement of this milestone is a firm confirmation of the ability of Domain Therapeutics' unique technology to address difficult GPCRs,' said Pascal Neuville, CEO of Domain Therapeutics. 'We are confident that its continued use will further the goals of this on-going research program.'

DTect-All(TM) is Domain's proprietary technology platform dedicated to identification of GPCR ligands, more specifically allosteric modulators. DTect-All(TM) addressees every GPCR including challenging ones such as orphan and peptidic receptors.

For this milestone, Domain will receive an undisclosed success fee.

About G Protein-Coupled Receptors (GPCRs)
GPCR targets account for 40-50 percent of currently marketed drugs and for more than USD 30 billion in annual sales. Their potential remains tremendous, as more than 300 are still unexploited because they are difficult to address. To tackle these, there is a need for new technologies, for example ones able to address orphan and peptidic GPCRs. Another challenge is the identification of allosteric modulators, a new class of GPCR ligands that are considered safer than standard agonist/antagonist molecules. Domain Therapeutics' DTect-All(TM) technology addresses both these unmet needs and will enable the company to participate broadly in the rapidly growing GPCR drug discovery efforts.

About Domain Therapeutics S.A.
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics uses DTect-All(TM), its innovative and proprietary technology platform, to identify allosteric modulators, including Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. The platform addresses difficult GPCRs such as orphan and peptidic receptors. The company's pipeline is composed of new chemical entities, ranging from hits to preclinical candidates, and targeting hot GPCRs for leading indications such as schizophrenia, Parkinson's disease, and diabetes.

For further information, please contact:

Andrew Lloyd & Associates
Andrew Lloyd / Neil Hunter
Tel: +44 1273 675100 /

Publisher Contact Information:

Andrew Lloyd & Associates
+44 1273 675100

Company profile of Domain Therapeutics (formerly Faust Pharmaceuticals)
Past press releases of Domain Therapeutics (formerly Faust Pharmaceuticals).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Oct 17€16.0MArtificial Intelligence
Oct 17€9.5MeLearning
Oct 17€1.7MInternet services
Oct 16€2.5MSecurity
Oct 16€6.0MInternet commerce
Oct 16€10.0MSecurity
Oct 16€19.0MInternet services

For information on Europe's most extensive database on technology funding click here!


Press Releases

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises 1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom

About usContact usLegal Information
Copyright 1999-2018
Emerging Technology Research Europe Inc. All rights reserved.